1. Phylogeny  
   Serine/threonine‑protein kinase H1 (PSKH1) is a member of the non‐specific serine/threonine protein kinase family (EC 2.7.11.1), a broad group of enzymes that are evolutionarily conserved across eukaryotes (anti2009nonspecificserinethreonineprotein pages 1-7). Within the human kinome, PSKH1 is grouped alongside other serine/threonine kinases that share a common catalytic domain and regulatory features. Orthologs of PSKH1 have been identified in several species, including mammals, yeast, and plants, reflecting the deep phylogenetic conservation of the kinase catalytic machinery (anti2009nonspecificserinethreonineprotein pages 13-16). Its inclusion with kinases that regulate diverse processes—from cell cycle control to RNA processing—suggests that PSKH1 lies within a core set of kinases whose origin dates back to the Last Eukaryotic Common Ancestor (anti2009nonspecificserinethreonineprotein pages 7-10).
2. Reaction Catalyzed  
   The catalytic reaction performed by PSKH1 conforms to the universal kinase mechanism in which ATP is used as a phosphate donor to phosphorylate serine or threonine residues on substrate proteins. The generalized reaction is:  
   ATP + protein-[L-serine or L-threonine] → ADP + protein-[phospho-L-serine or phospho-L-threonine] + H⁺ (anti2009nonspecificserinethreonineprotein pages 19-22, anti2009nonspecificserinethreonineprotein pages 34-37). Although specific substrates of PSKH1 are still under extensive study, the reaction mechanism is consistent with other non-specific serine/threonine kinases that utilize conserved catalytic motifs to promote phosphotransfer.
3. Cofactor Requirements  
   Like many protein kinases, PSKH1 requires divalent metal ions to facilitate the phosphotransfer reaction. Mg²⁺ is the most common cofactor needed for ATP binding and proper positioning within the active site (anti2009nonspecificserinethreonineprotein pages 19-22). In some contexts, Mn²⁺ may also support kinase activity, but Mg²⁺ remains the primary cofactor essential for catalytic function in serine/threonine kinases such as PSKH1.
4. Substrate Specificity  
   PSKH1 is proposed to participate in the regulation of pre-mRNA processing by phosphorylating components of nuclear splice factor compartments. In particular, it appears to target non-snRNP splicing factors containing serine/arginine-rich (SR) domains (Information section; anti2009nonspecificserinethreonineprotein pages 97-99). The phosphorylation of SR proteins by PSKH1 is thought to modulate their nucleoplasmic release and local concentration, which in turn influences alternative splicing decisions. Although a detailed consensus motif specific to PSKH1 substrates has not yet been fully elucidated, the kinase is expected to recognize features similar to other serine/threonine kinases in this family. Such enzymes sometimes prefer motifs with basic residues preceding the phosphoacceptor serine/threonine; hence, phosphorylation of SR proteins, known to contain repeated arginine–serine dipeptides, underscores the likely physiological substrate preference for PSKH1 (anti2009nonspecificserinethreonineprotein pages 37-39, anti2009nonspecificserinethreonineprotein pages 25-27).
5. Structure  
   The domain organization of PSKH1 is characteristic of serine/threonine kinases. It contains a central catalytic (kinase) domain that harbors the conserved motifs required for ATP binding and phosphotransfer. Although no high-resolution crystal structure specific to PSKH1 is reported in the provided context, predicted models (e.g., those from AlphaFold) likely reveal a typical kinase fold consisting of an N-terminal lobe mainly composed of β‑sheets and a C‑terminal lobe rich in α‑helices (anti2009nonspecificserinethreonineprotein pages 97-99). Unique to PSKH1 is its subcellular distribution—localization studies have shown that it is present in centrosomes, the Golgi apparatus, and the nucleus, suggesting additional targeting sequences or regulatory domains that mediate its partitioning within the cell (anti2009nonspecificserinethreonineprotein pages 97-99). Moreover, recent findings indicate that PSKH1 undergoes lipidation modifications, such as myristoylation and palmitoylation, which are known to contribute to the membrane association and spatial regulation of kinases (gormal2024locationlocationlocation pages 9-11). These post-translational modifications may serve to anchor PSKH1 near specialized nuclear or Golgi subdomains involved in spliceosome assembly.
6. Regulation  
   Regulation of PSKH1 activity is expected to involve several mechanisms common to serine/threonine kinases. Autophosphorylation events within the activation loop can enhance catalytic activity, while reversible phosphorylation of regulatory domains may serve to modulate substrate access and enzyme activity (anti2009nonspecificserinethreonineprotein pages 84-87). In addition, lipidation through myristoylation and palmitoylation—as reported in recent studies—likely influences its subcellular localization, thereby indirectly controlling access to spliceosomal substrates (gormal2024locationlocationlocation pages 9-11). Genetic studies have also indicated that mutations in PSKH1, such as a missense mutation (valine to aspartic acid) observed in an ENU-induced mouse model, lead to a significant reduction in protein expression (~58%), suggesting that protein stability and expression levels are an important facet of its regulation (ji2015anenuinducedpoint pages 77-83). While specific upstream kinases or phosphatases that modify PSKH1 remain to be fully characterized, its inclusion within the non-specific serine/threonine kinase family implies that it may be regulated in a manner analogous to other kinases involved in spliceosome regulation.
7. Function  
   The principal proposed function of PSKH1 is its involvement in pre-mRNA processing regulation. By phosphorylating key non-snRNP splicing factors—particularly those containing extensive serine/arginine-rich regions—PSKH1 can alter the assembly and dynamics of nuclear splice factor compartments (Information section; anti2009nonspecificserinethreonineprotein pages 97-99). Through the reversible phosphorylation of SR proteins, PSKH1 is likely to modulate the release of these proteins into the nucleoplasm, thereby influencing alternative splicing events. This regulatory capacity is critical for controlling gene expression and generating protein diversity, with broad implications for cell differentiation and function. PSKH1 expression patterns suggest that it may be ubiquitously expressed, although its enriched localization to the nucleus, centrosomes, and Golgi implies roles not only in splicing but also possibly in cell cycle regulation and intracellular trafficking (anti2009nonspecificserinethreonineprotein pages 7-10, ji2015anenuinducedpoint pages 77-83). Mutational analysis linking PSKH1 to kidney developmental defects further underscores its biological significance and suggests that disruption of its kinase activity can have pathological consequences.
8. Other Comments  
   There are currently no well‐established inhibitors reported specifically for PSKH1 in the literature provided, and detailed studies on its disease associations remain limited. However, the identification of a missense mutation in the Pskh1 gene that co-segregates with a nephronophthisis-like kidney phenotype in mice indicates that alterations in PSKH1 function or expression may contribute to disease (ji2015anenuinducedpoint pages 77-83). This mutation, which causes a substitution of a nonpolar valine to a negatively charged aspartic acid, likely disrupts the protein’s conformation and stability, as evidenced by the observed reduction in protein expression. Additionally, the role of lipidation in directing PSKH1 localization (myristoylation and palmitoylation) may serve as a potential regulatory node for future therapeutic design, especially if aberrant localization is linked to dysfunction in splicing regulation (gormal2024locationlocationlocation pages 9-11). Ongoing research is aimed at elucidating the complete set of substrates and interacting partners of PSKH1, as well as the downstream signaling pathways affected by its kinase activity. Such studies will be critical for understanding the full cellular impact of PSKH1 and for the potential development of targeted therapies in diseases where pre-mRNA splicing is dysregulated.
9. References  
   anti2009nonspecificserinethreonineprotein pages 1-7, anti2009nonspecificserinethreonineprotein pages 7-10, anti2009nonspecificserinethreonineprotein pages 13-16, anti2009nonspecificserinethreonineprotein pages 19-22, anti2009nonspecificserinethreonineprotein pages 25-27, anti2009nonspecificserinethreonineprotein pages 34-37, anti2009nonspecificserinethreonineprotein pages 37-39, anti2009nonspecificserinethreonineprotein pages 84-87, anti2009nonspecificserinethreonineprotein pages 97-99, gormal2024locationlocationlocation pages 9-11, ji2015anenuinducedpoint pages 77-83

References

1. (anti2009nonspecificserinethreonineprotein pages 19-22): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
2. (anti2009nonspecificserinethreonineprotein pages 25-27): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
3. (anti2009nonspecificserinethreonineprotein pages 37-39): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
4. (anti2009nonspecificserinethreonineprotein pages 84-87): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
5. (anti2009nonspecificserinethreonineprotein pages 97-99): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
6. (ji2015anenuinducedpoint pages 77-83): AR Ji. An enu-induced point mutation on chromosome eight causes a nephronophthisis-like kidney phenotype. Unknown journal, 2015.
7. (anti2009nonspecificserinethreonineprotein pages 34-37): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
8. (gormal2024locationlocationlocation pages 9-11): Rachel S Gormal, Ramon Martinez-Marmol, Andrew J Brooks, and Frédéric A Meunier. Location, location, location: protein kinase nanoclustering for optimised signalling output. eLife, Jan 2024. URL: https://doi.org/10.7554/elife.93902, doi:10.7554/elife.93902. This article has 11 citations and is from a domain leading peer-reviewed journal.
9. (anti2009nonspecificserinethreonineprotein pages 1-7): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
10. (anti2009nonspecificserinethreonineprotein pages 13-16): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.
11. (anti2009nonspecificserinethreonineprotein pages 7-10): B Anti. Non-specific serine/threonine protein kinase. Class 2 Transferases, pages 1-123, Jan 2009. URL: https://doi.org/10.1007/978-3-540-85699-3\_1, doi:10.1007/978-3-540-85699-3\_1. This article has 0 citations.